MAPT and diabetes mellitus: A recent meta‐analysis reviewed the evidence base for CSF tau and amyloid levels in people with diabetes and prediabetes and found that when only looking at those with diabetes, there were significantly higher levels of pTau compared with controls (Lu et al., 2018) consistent with our findings.